Aimmune Therapeutics (NASDAQ: AIMT) has recently received a number of price target changes and ratings updates:

  • 10/23/2017 – Aimmune Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $70.00 price target on the stock, up previously from $42.00.
  • 10/23/2017 – Aimmune Therapeutics had its price target raised by analysts at Credit Suisse Group from $36.00 to $45.00. They now have an “outperform” rating on the stock.
  • 10/21/2017 – Aimmune Therapeutics was given a new $38.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 10/16/2017 – Aimmune Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
  • 8/29/2017 – Aimmune Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at 32.94 on Tuesday. The stock’s market cap is $1.66 billion. The stock has a 50 day moving average of $25.01 and a 200 day moving average of $25.01. Aimmune Therapeutics, Inc. has a 1-year low of $14.87 and a 1-year high of $37.50.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Equities analysts anticipate that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current fiscal year.

In related news, insider Susan E. Barrowcliffe sold 18,390 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total value of $404,580.00. Following the completion of the sale, the insider now directly owns 3,223 shares of the company’s stock, valued at approximately $70,906. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stephen George Dilly sold 50,000 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total transaction of $1,073,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 318,890 shares of company stock valued at $7,788,062 in the last ninety days. Insiders own 24.56% of the company’s stock.

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.